Federated electronic health records research technology to support clinical trial protocol optimization: Evidence from EHR4CR and the InSite platform.

Clinical research Clinical trials Electronic health record Learning health systems Pharmaceutical industry

Journal

Journal of biomedical informatics
ISSN: 1532-0480
Titre abrégé: J Biomed Inform
Pays: United States
ID NLM: 100970413

Informations de publication

Date de publication:
02 2019
Historique:
received: 16 05 2018
revised: 30 10 2018
accepted: 21 12 2018
pubmed: 6 1 2019
medline: 17 3 2020
entrez: 6 1 2019
Statut: ppublish

Résumé

To determine if inclusion/exclusion (I/E) criteria of clinical trial protocols can be represented as structured queries and executed using a secure federated research platform (InSite) on hospital electronic health records (EHR) systems, to estimate the number of potentially eligible patients. Twenty-three clinical trial protocols completed during 2011-2017 across diverse disease areas were analyzed to construct queries that were executed with InSite using EHR records from 24 European hospitals containing records of >14 million patients. The number of patients matching I/E criteria of each protocol was estimated. All protocols could be formalized to some extent into a medical coding system (e.g. ICD-10CM, ATC, LOINC, SNOMED) and mapped to local hospital coding systems. The median number of I/E criteria of protocols tested was 29 (range: 14-47). A median of 55% (range 38-89%) of I/E criteria in each protocol could be transformed into a computable format. The median number of eligible patients identified was 26 per hospital site (range: 1-134). Clinical trial I/E eligibility criteria can be structured computationally and executed as queries on EHR systems to estimate the patient recruitment pool at each site. The results further suggest that an increase in structured coded information in EHRs would increase the number of I/E criteria that could be evaluated. Additional work is needed on broader deployment of federated platforms such as InSite.

Identifiants

pubmed: 30611012
pii: S1532-0464(18)30231-4
doi: 10.1016/j.jbi.2018.12.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103090

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Brecht Claerhout (B)

Custodix N.V., Gent, Belgium.

Dipak Kalra (D)

European Institute for Innovation through Health Data (i-HD), Brussels, Belgium.

Christina Mueller (C)

Custodix N.V., Gent, Belgium.

Gurparkash Singh (G)

Janssen Research & Development LLC, Fremont, United States.

Nadir Ammour (N)

Sanofi-Aventis R&D, Chilly-Mazarin, France.

Laura Meloni (L)

Custodix N.V., Gent, Belgium.

Juuso Blomster (J)

Turku University Hospital, Turku, Finland.

Mark Hopley (M)

Boehringer-Ingelheim, Ingelheim, Germany.

George Kafatos (G)

Amgen, Uxbridge, UK.

Almenia Garvey (A)

ICON PLC, Paris, France.

Peter Kuhn (P)

Comprehensive Cancer Center Ulm, University Hospital Ulm, Ulm, Germany; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.

Martine Lewi (M)

Janssen Pharmaceuticals, Beerse, Belgium.

Bart Vannieuwenhuyse (B)

Janssen Pharmaceuticals, Beerse, Belgium.

Benoît Marchal (B)

F. Hoffmann-La Roche, Basel, Switzerland.

Ketan Patel (K)

AstraZeneca, Cambridge, UK.

Christoph Schindler (C)

Medizinische Hochschule Hannover, Hannover, Germany.

Mats Sundgren (M)

AstraZeneca, Gothenburg, Sweden. Electronic address: mats.sundgren@astrazeneca.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH